691 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
BIIB Biogen Inc. $279.68 $59.17B N/A
Article Searches
U.S. Biotech/Pharma Sector Daily Observations Letter: March 20, 2018 https://seekingalpha.com/article/4157958-u-s-biotech-pharma-sector-daily-observations-letter-march-20-2018?source=feed_sector_healthcare Mar 21, 2018 - The broad market is still trying to make up its mind about the overall direction after another consolidation day. Celgene showed confidence in the tau hypothesis of Alzheimer’s disease, AD by signing
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene http://www.zacks.com/stock/news/296029/the-zacks-analyst-blog-highlights-biogen-abbvie-novartis-teva-and-celgene?cid=CS-ZC-FT-296029 Mar 19, 2018 - The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
Biogen's Key Variable: Its Neuroscience Pipeline https://seekingalpha.com/article/4157396-biogens-key-variable-neuroscience-pipeline?source=feed_sector_healthcare Mar 18, 2018 - Q4 2017 had record revenue, boosted by Spinraza ramp.Expansion beyond MS to Alzheimer’s and other neural diseases would be transformative.Biogen's goal is to become the “fastest-growing large-cap biot
Why Multiple Sclerosis is a Promising but Risky Space? http://www.zacks.com/stock/news/295949/why-multiple-sclerosis-is-a-promising-but-risky-space?cid=CS-ZC-FT-295949 Mar 16, 2018 - Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.
Ronald Muhlenkamp's Largest Buys of the 4th Quarter http://www.gurufocus.com/news/653020/ronald-muhlenkamps-largest-buys-of-the-4th-quarter Mar 15, 2018 - Ronald Muhlenkamp's Largest Buys of the 4th Quarter, Stocks: PHM,THO,AZO,EPD,CE,ADS,BIIB, Pioneer Investments,Joel Greenblatt, release date:Mar 15, 2018
Updating Our Thoughts On Celgene https://seekingalpha.com/article/4156489-updating-thoughts-celgene?source=feed_sector_healthcare Mar 14, 2018 - The combination of disruptive new discoveries coupled with burgeoning demand thanks to the aging demographics of the world’s population sets the biotech space for a potential virtuous long-term cycle.
6 Five-Star Quality Companies for 2018 http://www.gurufocus.com/news/652594/6-fivestar-quality-companies-for-2018 Mar 14, 2018 - 6 Five-Star Quality Companies for 2018, Stocks: BIIB,CERN,EW,JKHY,NTES,TYL,BAX, Warren Buffett, Ron Baron, Richard Pzena, release date:Mar 14, 2018
Bull of the Day: Regeneron (REGN) http://www.zacks.com/commentary/153268/bull-of-the-day-regeneron-regn?cid=CS-ZC--153268 Mar 14, 2018 - Bull of the Day: Regeneron (REGN)
Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy http://www.zacks.com/stock/news/295636/biotech-stock-roundup-regn-cuts-praluent-price-orex-to-file-for-bankruptcy?cid=CS-ZC-FT-295636 Mar 14, 2018 - The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Is Biogen Inc. a Buy? https://www.fool.com/investing/2018/03/14/is-biogen-inc-a-buy.aspx?source=iedfolrf0000001 Mar 14, 2018 - The biotech has a lot of promise -- but some big risks.

Pages: 123456...70

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GILD Gilead Sciences, Inc. NASDAQ $76.92 $100.76B
BLUE bluebird bio, Inc. NASDAQ $189.3 $9.46B
SGEN Seattle Genetics, Inc. NASDAQ $54.86 $8.67B
QGEN Qiagen N.V. NYSE $33.82 $7.66B
QGEN Qiagen N.V. NASDAQ $33.82 $7.66B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Biogen
BIIB - Google Finance https://www.google.com/finance?q=BIIB Industry related info and international coverage Summary News
BIIB - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BIIB Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options